Shares of Illumina, PacBio, Myriad Rise Sharply in January | GenomeWeb

This article has been corrected to fix erroneous information regarding Qiagen. The firm's Q4 revenues increased 5 percent, not decreased 5 percent, as the previous version of the article stated. Also, Qiagen didn't sign a recent companion diagnostic alliance with Amgen.

NEW YORK (GenomeWeb News) – Illumina, Pacific Biosciences, and Myriad Genetics led a group of companies which saw their stocks increase more than 20 percent in January from December as the GenomeWeb Daily News Index rose nearly 7 percent month over month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.